Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Touyun Biotech Group's Enterprise Value is HK$885.44 Mil.
Touyun Biotech Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-32.60 Mil. Therefore, Touyun Biotech Group's EV-to-FCF for today is -27.16.
The historical rank and industry rank for Touyun Biotech Group's EV-to-FCF or its related term are showing as below:
HKSE:01332'
s EV-to-FCF Range Over the Past 10 Years
Min: -70.79 Med: -12 Max: 13.52
Current: -27.16
During the past 13 years, the highest EV-to-FCF of Touyun Biotech Group was 13.52. The lowest was -70.79. And the median was -12.00.
HKSE:01332's EV-to-FCF is ranked worse than 100% of 242
companies
in the Packaging & Containers industry
Industry Median: 17.19
vs HKSE:01332: -27.16
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Touyun Biotech Group (HKSE:01332) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Touyun Biotech Group's PE Ratio (TTM) for today is calculated as:
Touyun Biotech Group's share price for today is HK$0.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Touyun Biotech Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Touyun Biotech Group EV-to-FCF Related Terms
Touyun Biotech Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Touyun Biotech Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaging & Containers subindustry, Touyun Biotech Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Touyun Biotech Group EV-to-FCF vs Packaging & Containers Industry
For the Packaging & Containers industry and Consumer Cyclical sector, Touyun Biotech Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Touyun Biotech Group's EV-to-FCF falls into.
Touyun Biotech Group's current Enterprise Value is HK$885.44 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Touyun Biotech Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-32.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Touyun Biotech Group (HKSE:01332) has a EV-to-FCF of -27.16 as of Aug. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Touyun Biotech Group and its competitors. According to the industry distribution chart, Touyun Biotech Group ranks #999999 out of 242 companies in the Packaging & Containers industry.
Is Touyun Biotech Group's EV-to-FCF too high?
Touyun Biotech Group's current EV-to-FCF is -27.16. Based on the distribution chart, Touyun Biotech Group ranks #999999 out of 242 companies in the Packaging & Containers industry, which is in the bottom quartile relative to peers. Overall, Touyun Biotech Group has a GF Score™ of 22/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Touyun Biotech Group's EV-to-FCF compare to SW and PKG?
According to the Packaging & Containers industry distribution chart, Touyun Biotech Group ranks #999999 out of 242 companies for EV-to-FCF. This places Touyun Biotech Group in the lower half of its industry. The industry median EV-to-FCF is 17.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Packaging & Containers company?
The median EV-to-FCF among Packaging & Containers companies is 17.19, based on 242 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Touyun Biotech Group and its competitors. For the Packaging & Containers industry, the median EV-to-FCF is 17.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Touyun Biotech Group's current EV-to-FCF is -27.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Touyun Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, Touyun Biotech Group (HKSE:01332) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.16, compared to a current price of HK$0.15 — trading 6.3% below its estimated fair value. The current EV-to-FCF is -27.16. Touyun Biotech Group's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Touyun Biotech Group (HKSE:01332), the current EV-to-FCF is -27.16 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Touyun Biotech Group (HKSE:01332) Overvalued in 2026?
Based on GuruFocus' analysis, Touyun Biotech Group stock appears to be undervalued.
The current stock price of HK$0.15 is trading 6.3% below its estimated GF Value™ of HK$0.16.
GuruFocus considers Touyun Biotech Group to be Fairly Valued.
Key valuation signals for HKSE:01332:
EV-to-FCF: -27.16
GF Value™: HK$0.16 vs. price of HK$0.15 (6.3% below fair value)
No single metric tells the full story. See the HKSE:01332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Touyun Biotech Group Ltd is principally engaged in the (i) the manufacture and sale of packaging products; (ii) investments and trading in securities and money lending, and (iii) production and sale of Chlamydomonas reinhardtii, micro-algae and related products. The company generates majority of its revenue from packaging products segment.
22GF Score
Get the complete analysis for HKSE:01332
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01332 has been successfully added to your 
